A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Phase 2 Withdrawn
Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Phase 2 Withdrawn
DEC-C and Thioguanine for R/R AML
Phase 2 Withdrawn
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Phase 2 Withdrawn
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
Phase 2 Withdrawn
68-Ga-FAPI PET Imaging in Malignancy
Phase 2 Withdrawn
REPAIR
Phase 2 Withdrawn
The Effect of Cannabis in Pancreatic Cancer
Phase 2 Withdrawn
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Phase 2 Withdrawn
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Phase 2 Withdrawn
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
Phase 2 Withdrawn
RALT
Phase 2 Withdrawn
PECULIAR
Phase 2 Withdrawn
Study of Sodium Bicarbonate in Restoring Blocked Catheters
Phase 2 Withdrawn
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
Phase 2 Withdrawn
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
Phase 2 Withdrawn
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Phase 2 Withdrawn
Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
Phase 2 Withdrawn
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
Phase 2 Withdrawn
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Phase 2 Withdrawn
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Phase 2 Withdrawn
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Phase 2 Withdrawn
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Phase 2 Withdrawn
Lenalidomide and Obinutuzumab for Previously Untreated CLL
Phase 2 Withdrawn
RESCUE
Phase 2 Withdrawn
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
Phase 2 Withdrawn
HYPOLAN
Phase 2 Withdrawn
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
Phase 2 Withdrawn
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
Phase 2 Withdrawn
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Phase 2 Withdrawn
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
Phase 2 Withdrawn
Pharmacology Study of Aerosolized Liposomal
Phase 2 Withdrawn
THOR
Phase 2 Withdrawn
ASPIDIA
Phase 2 Withdrawn
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
Phase 2 Withdrawn
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
Phase 2 Withdrawn
U-CARE:TeenCan
Phase 2 Withdrawn
Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients
Phase 2 Withdrawn
EVAMP
Phase 2 Withdrawn
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
Phase 2 Withdrawn
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Phase 2 Withdrawn
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
Phase 2 Withdrawn
Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis
Phase 2 Withdrawn
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Phase 2 Withdrawn
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Phase 2 Withdrawn
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
Phase 2 Withdrawn
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 2 Withdrawn
Intravenous (IV) Lidocaine for Opioid-refractory Pain
Phase 2 Withdrawn
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Phase 2 Withdrawn
15 enrolled